Neogen Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEOG research report →
Range $13 – $14
Price Chart
About the company
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed.
- CEO
- Mikhael Nassif
- IPO
- 1989
- Employees
- 2,636
- HQ
- Lansing, MI, US
Get TickerSpark's AI analysis on NEOG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.30B
- P/E
- -42.85
- Fwd P/E
- 31.65
- PEG
- 0.03
- P/S
- 2.68
- P/B
- 1.13
- EV/EBITDA
- 28.26
- Div Yield
- 0.00%
- Gross Margin
- 47.40%
- Op Margin
- -0.83%
- Net Margin
- -6.35%
- ROE
- -2.68%
- ROIC
- -0.19%
Latest fiscal year · YoY change
- Revenue
- $870.40M-2.7%
- Gross Profit
- $408.50M-3.1%
- Op Income
- $-21,600,000
- Net Income
- $-7,900,000+99.3%
- EPS
- $-0.04+99.2%
- OCF Growth
- +42.8%
- FCF Growth
- +168.8%
- 52W High
- $14.26
- 52W Low
- $5.37
- 50D MA
- $12.16
- 200D MA
- $10.53
- Beta
- 1.86
- RSI (14)
- 34
- Avg Volume
- 3.50M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Neogen reported an encouraging start to fiscal 2027 with 8.1% core revenue growth, margin expansion, and a raised full-year outlook, while continuing to invest in commercial execution, innovation, and the Petrifilm transition.· October 6, 2026
- Q1 revenue was $222.8 million with core growth of 8.1%; adjusted EPS was $0.08 and adjusted EBITDA was $41.6 million, with 18.7% margin.
- Food Safety revenue was $163.2 million, up 8.1% core, and Animal Safety revenue was $59.6 million, up 8% core.
- Adjusted gross margin increased to 49.8%, up 30 basis points year over year; adjusted operating expenses were roughly flat.
- Management raised fiscal 2027 guidance to $885 million-$890 million in revenue and $181 million-$183 million in adjusted EBITDA.
- The company said the Petrifilm manufacturing transfer remains on track, with full validation of the first SKU completed and the planned multi-quarter transfer expected to begin next month.
Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 8.1% core. Food Safety revenue was $163.2 million, up 8.1% core, and Animal Safety revenue was $59.6 million, up 8% core. Gross margin was 47.4% and adjusted gross margin was 49.8%, up 30 basis points year over year. Adjusted EBITDA was $41.6 million, for an 18.7% margin, and adjusted EPS was $0.08. Free cash flow was $4.7 million, about $18 million better than last year. For fiscal 2027, management raised revenue guidance to $885 million-$890 million and adjusted EBITDA guidance to $181 million-$183 million. They said the first half should be in line with Q1 on EBITDA margin, with first-half core growth expected at about 3.5%, and reiterated that full-year EBITDA margins should be roughly similar to fiscal 2026.
Mike Nassif framed the quarter as evidence that Neogen’s turnaround work is starting to take hold, emphasizing better commercial execution, a rebuilding innovation pipeline, and improved supply-demand-inventory coordination. He repeatedly stressed that the company is shifting from stabilization into scaling its fundamentals, with a focus on consistent growth, margin expansion, and long-term leadership in food safety and animal safety. His tone was positive but measured, noting there is still “work ahead” and that discipline and accountability remain priorities.
Bryan Riggsbee highlighted the main financial drivers: 8.1% core growth, adjusted gross margin of 49.8% up 30 basis points, adjusted EBITDA margin of 18.7% up 170 basis points, and free cash flow of $4.7 million versus about $18 million of year-over-year improvement. He said operating expenses were roughly flat as higher R&D and G&A were offset by lower sales and marketing, including logistics savings and the divestiture of cleaners/disinfectants. On the balance sheet, Neogen ended with about $774 million of debt and $172 million of cash, paid down $20 million of term loan in June and another $10 million at the end of September, and expects roughly $140 million of net proceeds from the genomics divestiture to go primarily to debt reduction. He also raised fiscal 2027 guidance to $885 million-$890 million in revenue and $181 million-$183 million in adjusted EBITDA.
Analysts focused on how to interpret the full-year EBITDA margin guide versus the stronger Q1 margin, and Riggsbee clarified that the second quarter and first half should be similar to Q1, with some investments and margin initiatives weighted toward the back half of the year. Questions also centered on whether the company is already taking share; management pointed to competitive conversions, strategic account wins, and a new global account model as early signs of share gain. Several questions addressed the Petrifilm transition, with management outlining four key controls: customer continuity, safety stock, supplier management, and disciplined SKU sequencing. On the Hinalea collaboration, Nassif said it is one of several possible partnerships and that Neogen sees technology licensing and collaborations as part of its innovation strategy.
The call showed improving core growth across both segments, with management saying commercial changes are producing competitive wins and strategic account progress. Free cash flow improved sharply, gross margin expanded, and management raised full-year revenue and EBITDA guidance while describing the business as early in a multi-quarter operating improvement.
Management said some Q1 growth benefited from order timing and easier comparisons, so the run rate may not fully reflect underlying demand. EBITDA margin is expected to stay around Q1 levels in the first half because of planned investments and transition-related costs, and the Petrifilm transfer still carries execution risk despite the first SKU validation. The genomics divestiture is also still subject to regulatory review, with final approval expected by the end of December.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 218.31M
- Float Shares
- 216.15M
of shares held by institutions
325 13F filers
Buy/sell ratio 2.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NEOG, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 32.98M | ▼ 450.82K |
| Vanguard Group Inc | 23.80M | ▼ 161.32K |
| Neuberger Berman Group LLC | 14.91M | ▼ 1.66M |
| Vanguard Portfolio Management LLC | 12.97M | ▼ 68.99K |
| Dimensional Fund Advisors LP | 10.28M | ▲ 456.42K |
| Vanguard Capital Management LLC | 9.67M | ▲ 12.80K |
| Sg Americas Securities, LLC | 9.35M | ▲ 3.09M |
| State Street Corp | 8.92M | ▼ 28.61K |
| Ing Groep Nv | 8.75M | ▼ 353.96K |
| T. Rowe Price Investment Management, Inc. | 8.50M | ▼ 835.59K |
| Gates Capital Management, Inc. | 7.42M | ▼ 1.33M |
| Cibc World Markets Corp | 6.86M | ▲ 6.86M |
Held by 327 ETFs
Biggest fund positions in NEOG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Yarwood Jeremy | other | 16,207 |
| Nov 3, 26 | Yarwood Jeremy | other | 7,156 |
| Nov 4, 26 | Yarwood Jeremy | sell | 9,051 |
| Nov 2, 26 | Freels Joe B | other | 31,311 |
| Nov 2, 26 | Freels Joe B | other | 6,345 |
| Oct 29, 26 | Hastings Gregory S | other | 1,211 |
| Oct 29, 26 | Hastings Gregory S | other | 337 |
| Oct 29, 26 | Hastings Gregory S | other | 1,211 |
| Oct 29, 26 | Woteki Catherine E | other | 1,776 |
| Oct 29, 26 | Woteki Catherine E | other | 1,776 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NEOG coverage
Recent articles, reports, and earnings notes.
No research on NEOG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEOG report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
globenewswire.com · Nov 10
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
prnewswire.com · Nov 5
Neogen (NEOG) Up 6.7% Since Last Earnings Report: Can It Continue?
zacks.com · Nov 5
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
globenewswire.com · Nov 3
Neogen® To Participate in 2026 UBS Global Healthcare Conference
businesswire.com · Nov 3
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
prnewswire.com · Oct 29
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.